Lasa Supergenerics Ltd. (LASA) AI Stock Analysis

Top Page

Lasa Supergenerics Ltd.

(NSE:LASA)

Select Model

Rating:38Underperform

Price Target:INR 4.50▼(-10.54% Downside)

Action:downgraded

Date:09/06/26

Primarily driven by weak financial performance from persistent losses and cash flow issues, with bearish technical indicators and poor valuation metrics from negative earnings further weighing on the score.

Positive Factors

Low leverageRelatively low leverage gives LASA more balance-sheet flexibility than a highly indebted business and limits the immediate burden of interest and refinancing. This can preserve options to fund operations or pursue recovery, although it does not offset persistent operating losses.

Negative Factors

Severe revenue contractionA roughly 74% year-over-year revenue decline signals a major deterioration in commercial scale and customer demand or product economics. If the contraction persists, lower plant utilization and reduced operating leverage could continue weakening profitability and limit funds available for recovery.

Lasa Supergenerics Ltd. (LASA) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 240.49M
Dividend Yield: ―
Average Volume (3M): 6,639
Price to Earnings (P/E): -1.4
Beta (1Y): 1.31
Revenue Growth: -95.17%
EPS Growth: 50.07%
Country: India
Employees: 9
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Lasa Supergenerics Ltd. Business Overview & Revenue Model

Company Description

Lasa Supergenerics Limited, founded in 2016 and based in Mumbai, India, specializes in the development, manufacturing, and commercialization of various healthcare products for both human and animal well-being. Its operations predominantly cater to th...

How the Company Makes Money

LASA primarily makes money by manufacturing and selling pharmaceutical APIs and intermediates to other pharmaceutical companies (e.g., generic drug manufacturers and formulators) that use these inputs to produce finished medicines. Revenue is generat...

Lasa Supergenerics Ltd. Financial Statement Overview

Summary

Weak income statement with persistent net losses and revenue declines, eroding equity on the balance sheet, and recent negative operating cash flows signal high financial risk.

Income Statement

15Very Negative

Balance Sheet

35Negative

Cash Flow

20Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	63.56M	251.41M	1.42B	1.04B	1.30B	1.37B
Gross Profit	-84.79M	-68.91M	362.61M	286.95M	-111.88M	427.84M
EBITDA	-82.48M	-282.04M	-43.91M	-64.66M	-246.85M	84.12M
Net Income	-165.50M	-340.90M	-147.57M	-217.31M	-386.21M	-53.31M
Balance Sheet
Total Assets	0	665.67M	1.02B	1.51B	1.64B	2.09B
Cash, Cash Equivalents and Short-Term Investments	6.97M	6.97M	7.90M	14.96M	21.78M	172.17M
Total Debt	0	97.47M	21.27M	220.76M	217.70M	201.71M
Total Liabilities	-496.23M	169.44M	178.19M	541.92M	455.69M	512.87M
Stockholders Equity	496.23M	496.23M	837.13M	966.76M	1.18B	1.58B
Cash Flow
Free Cash Flow	-899.00K	0	-28.24M	21.39M	-173.00M	92.12M
Operating Cash Flow	2.59M	-80.67M	-28.24M	21.39M	-173.00M	92.12M
Investing Cash Flow	-1.00M	3.27M	81.52M	-3.98M	111.95M	-29.12M
Financing Cash Flow	-1.46M	77.53M	-56.62M	-19.32M	-41.61M	-403.00K

Lasa Supergenerics Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price5.03

Price Trends

50DMA6.05Negative

100DMA6.70Negative

200DMA7.46Negative

Market Momentum

MACD-0.28Negative

RSI15.77Positive

STOCH0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LASA, the sentiment is Negative. The current price of 5.03 is below the 20-day moving average (MA) of 5.34, below the 50-day MA of 6.05, and below the 200-day MA of 7.46, indicating a bearish trend. The MACD of -0.28 indicates Negative momentum. The RSI at 15.77 is Positive, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:LASA.

Lasa Supergenerics Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:LASA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:PAR	73Outperform	INR 1.41B	9.73	―	―	9.40%	34.12%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:BALPHARMA	49Neutral	INR 1.29B	18.03	―	1.47%	13.51%	-14.80%
IN:BIOFILCHEM	47Neutral	INR 471.94M	96.99	―	―	9.31%	-82.71%
IN:VIVIMEDLAB	40Underperform	INR 506.60M	-0.26	―	―	-39.80%	-452.04%
IN:LASA	38Underperform	INR 252.01M	-1.42	―	―	-95.17%	50.07%
IN:MANGALAM	37Underperform	INR 457.75M	-1.18	―	―	-22.27%	-291.72%

* General Sector Average

Performance Comparison

IN:LASA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:LASA	Lasa Supergenerics Ltd.	5.03	-6.67	-57.01%
IN:BALPHARMA	Bal Pharma Limited	81.20	0.52	0.64%
IN:BIOFILCHEM	Biofil Chemicals & Pharmaceuticals Ltd.	29.00	-11.69	-28.73%
IN:MANGALAM	Mangalam Drugs & Organics Ltd.	28.92	-38.26	-56.95%
IN:PAR	Par Drugs and Chemicals Limited	114.67	12.95	12.73%
IN:VIVIMEDLAB	Vivimed Labs Limited	6.11	1.21	24.69%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026

Lasa Supergenerics Ltd. AI Stock Analysis

Top Page